AZN · story · 8 November
AstraZeneca · 4 headlines from 4 outlets, on 8 November 2026.
The India unit will launch Datverzo in November, with Q2 revenue up 30%.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
EHealth Magazine is the largest at 7.5, ahead of scanx.trade (5.8). Scanx.trade is the smallest at 5.8.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| eHealth Magazine | 7.5 |
| scanx.trade | 5.8 |
| Kalkine India | 5.8 |
| Business Upturn | 5.8 |
| Outlet | Headlines | Average tone |
|---|---|---|
| eHealth Magazine | 1 | +7.5 |
| scanx.trade | 1 | +5.8 |
| Kalkine India | 1 | +5.8 |
| Business Upturn | 1 | +5.8 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +7.5 | Indian arm reports strong quarterly revenue growth and plans new product launch. |
| +5.8 | Indian subsidiary plans a new breast cancer product launch. |
| +5.8 | Indian subsidiary bringing breast cancer therapy to market. |
| +5.8 | Indian unit schedules breast cancer treatment rollout, adding to its portfolio. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.